Roquefort Therapeutics (ROQ) RNS Announcements

Add to Alert list
Date Time Source Announcement
26 Apr 2024 07:00 AM
RNS
Annual Report & Financial Statements - 31 Dec 2023
05 Apr 2024 07:00 AM
RNS
Response to Share Price Movement
11 Mar 2024 07:00 AM
RNS
Positive Results: Midkine mRNA and STAT-6 siRNA
06 Feb 2024 07:00 AM
RNS
Operations Update
24 Nov 2023 07:00 AM
RNS
Change of Auditor
06 Nov 2023 07:00 AM
RNS
Significant Mesodermal Killer Cell Milestone
27 Sep 2023 07:00 AM
RNS
Interim Results to 30 June 2023
22 Sep 2023 11:42 AM
RNS
Investor Presentation via Investor Meet Company
14 Aug 2023 07:00 AM
RNS
Expansion of Patent Portfolio
07 Aug 2023 07:00 AM
RNS
Development of New Novel siRNA Therapeutics
02 Aug 2023 07:00 AM
RNS
Director/PDMR Shareholding
12 Jul 2023 10:27 AM
RNS
Director/PDMR Shareholding
29 Jun 2023 10:05 AM
RNS
Results of AGM
29 Jun 2023 07:00 AM
RNS
AGM Statement
27 Jun 2023 07:00 AM
RNS
Investor Presentation via Investor Meet Company
26 Jun 2023 02:41 PM
RNS
Director/PDMR Shareholding
26 Jun 2023 10:36 AM
RNS
Director/PDMR Shareholding
26 Jun 2023 10:00 AM
RNS
Director/PDMR Shareholding
22 Jun 2023 07:00 AM
RNS
RNA Medicine Shows In Vitro Anti-Cancer Efficacy
19 Jun 2023 07:00 AM
RNS
Antibody Program Results & Orphan Drug Indication
13 Jun 2023 07:00 AM
RNS
Anti-Cancer MDK mRNA - Positive in vitro Results
07 Jun 2023 10:11 AM
RNS
Restoration of Trading
06 Jun 2023 07:00 AM
RNS
Notice of Annual General Meeting
05 Jun 2023 07:00 AM
RNS
Annual Report & Financial Statements - 31 Dec 2022
02 May 2023 07:56 AM
RNS
Suspension of Trading Pending 2022 Annual Report
13 Mar 2023 07:30 AM
RNS
Confirmation of No Exposure to Silicon Valley Bank
08 Mar 2023 07:00 AM
RNS
Creation of New Novel Family of mRNA Therapeutics
06 Mar 2023 07:00 AM
RNS
Formation of Scientific Advisory Board
01 Mar 2023 07:00 AM
RNS
Company Presentation
21 Feb 2023 07:00 AM
RNS
Investor Presentation
20 Feb 2023 07:00 AM
RNS
Randox Licence and Royalty Agreement
24 Jan 2023 07:00 AM
RNS
MDK Oncology Antibodies Demonstrate In-Vivo Safety
18 Jan 2023 08:36 AM
RNS
Holding(s) in Company
16 Jan 2023 07:00 AM
RNS
Appointment of Auditor
09 Jan 2023 07:00 AM
RNS
Operations Update
05 Dec 2022 08:07 AM
RNS
Presentation of Midkine Oligonucleotide Program
01 Dec 2022 02:00 PM
RNS
Resignation of Auditor
25 Oct 2022 07:00 AM
RNS
Midkine Antibody Program - Festival of Biologics
11 Oct 2022 07:00 AM
RNS
ROQ Presents Study Results at the ESGCT Conference
28 Sep 2022 07:00 AM
RNS
Director/PDMR Shareholding
26 Sep 2022 02:30 PM
RNS
Director/PDMR Shareholding
23 Sep 2022 07:00 AM
RNS
Interim Results to 30 June 2022
16 Sep 2022 08:00 AM
RNS
Investor Presentation
16 Sep 2022 07:01 AM
RNS
Board and Management Appointments
16 Sep 2022 07:00 AM
RNS
Acquisition Completion, Admission & Voting Rights
15 Sep 2022 12:26 PM
RNS
Notice of Admission
13 Sep 2022 11:08 AM
RNS
Publication of Prospectus
11 Aug 2022 07:00 AM
RNS
Pre-clinical Program & Transaction Update
20 Jul 2022 07:00 AM
RNS
Appointment of Joint Broker
15 Jul 2022 07:00 AM
RNS
Commencement of Trading on US OTCQB Venture Market
UK 100

Latest directors dealings